Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.17 - $0.34 $62,578 - $125,156
-368,106 Reduced 23.57%
1,193,701 $226,000
Q1 2022

May 13, 2022

SELL
$0.25 - $0.43 $79,131 - $136,106
-316,527 Reduced 16.85%
1,561,807 $491,000
Q4 2021

Feb 11, 2022

BUY
$0.34 - $1.0 $638,633 - $1.88 Million
1,878,334 New
1,878,334 $657,000
Q3 2021

Nov 12, 2021

SELL
$0.96 - $1.62 $92,160 - $155,520
-96,000 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$1.09 - $1.49 $488,876 - $668,281
-448,511 Reduced 82.37%
96,000 $134,000
Q1 2021

May 13, 2021

BUY
$1.26 - $2.02 $10,183 - $16,325
8,082 Added 1.51%
544,511 $741,000
Q4 2020

Feb 10, 2021

BUY
$0.9 - $1.54 $287,334 - $491,661
319,261 Added 147.01%
536,429 $719,000
Q3 2020

Nov 13, 2020

BUY
$0.87 - $2.08 $127,200 - $304,110
146,207 Added 206.04%
217,168 $206,000
Q2 2020

Aug 13, 2020

BUY
$1.08 - $4.0 $76,637 - $283,844
70,961 New
70,961 $110,000

Others Institutions Holding CWBR

# of Institutions
1
Shares Held
1.14K
Call Options Held
0
Put Options Held
0

About CohBar, Inc.


  • Ticker CWBR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,906,940
  • Market Cap $1.57M
  • Description
  • CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute...
More about CWBR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.